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Objectives. This study sought to determine the eJicacy and 
safety of arbutamine echocardiography in inducing myocardial 
ischemia and detecting coronary artery disease. 
Background. Exercise and pharmacologic stress echocardiog. 
raphy are clinically accepted techniques for detecting coronary 
artery disease. Arbutamine is a new synthetic beta-adrenoeeptor 
agonist developed specifically as a stress agent. Arbutamine is 
delivered by a new computerized rug delivery device that adjusts 
the rate of drug infusion according to the patient's heart rate 
response during stress testing. 
Methods. The sensitivity of arbutamine echocardiography was 
determined in 143 patients who had coronary artery disease 
documented by coronary angiography. A subset of these patients 
(n = 114) also underwent exercise echocardiography. The speci- 
ficity, or normalcy, of arbutamine echocardiography was deter- 
mined in 54 patients considered to have a low likelihood of 
coronary artery disease. 
Results. Among those patients who had both stress test results, 
the incidence of inducing myocardial ischemia (new or worsening 
wall motion abnormalities) was 79% (95% confidence interval 
[CI] 69% to 86% n = 98) for arbutamine and 77% (95% CI 67% 
to 85%, n = 98) for exercise echocardiography. The sensitivity of 
detecting coronary artery disease (ischemia or rest wall motion 
abnormality) was 87% (95% CI 79% to 93%, n = 101) for 
arbutamine and 83% (95% CI 74% to 90%, n = 101) for exercise 
echocardiography. The specificity (normalcy) of arbutamine cho- 
cardiography was 96% (95% C187% to 100%, n = 52). Arbutamine 
was well tolerated, and there were no serious adverse events. 
Conclusions. Arbutamine echocardiography is an effective and 
safe pharmacologic stress test technique for diagnosing or exclud- 
ing the presence of coronary artery disease. The ability of arbu- 
tamine stress to induce myocardial ischemia, detectable by echo- 
cardiography, was comparable to that for exercise. 
(J Am CoU Cardioi 1995;26:1168-75) 
Exercise and pharmacologic stress echocardiography are clin- 
ically established techniques for detecting coronary artery 
disease (1-5). Dobutamine has become the predominant phar- 
macologic stress agent used for diagnostic testing in conjunc- 
tion with echocardiography (3-5). Arbutamine, a new synthetic 
catecholamine, was developed specifically as a cardiovascular 
stress agent. It is a potent, short-acting, nonselective beta- 
adrenoceptor agonist with mild alpha-adrenoceptor activity. In 
nonischemic (6) and ischemic (7) animals, arbutamine in- 
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creases heart rate and left ventricular contractility in a dose- 
dependent manner without a significant decrease in arterial 
pressure. Compared with dobutamine, which selectively in- 
creases contractility, arbutamine levates heart rate and con- 
tractility with similar potency (6). This greater chronotropic 
activity may offer a potential advantage for arbutamine in the 
induction of ischemia (8). 
Arbutamine is administered with a unique, computerized 
infusion device that titrates the infusion rate in response to 
changes in the patient's heart rate. The physician selects arate of 
heart rate increase (heart rate slope) from 4 to 12 beats/min per 
rain and a maximal heart rate (heart rate target). The device 
continuously monitors and records heart rate and blood pres- 
sure (Fig. 1) and provides audible and visual "alerts" and 
"alarms" to warn the physician of potentially significant clinical 
situations. 
The objectives of the present study were to determine the 
efficacy and safety of arbutamine and its drug delivery system 
in inducing ischemia nd detecting coronary artery disease in 
conjunction with echocardiography. 
© 1995 by the American ('t~llcgc ~1 Cardi~h~) 0735-1097/95/$9.5(I 
0735-1097(95)00296-O 
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Figure 1. Arbutamine stress test printout show- 
ing patient heart rate (HR), blood pressure 
(BP) and infusion rate plotted over time. 
BPM = beats per minute. 
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Methods  
Patient selection. Patients from 28 sites in six countries 
were recruited (Table 1). Arbutamine chocardiography was 
performed in two different patient groups between May 1992 
and June 1993. Sensitivity was determined in patients with 
documented coronary artery disease (group 1), and specificity 
or normalcy was assessed in a separate study in patients with a 
low likelihood of coronary artery disease (group 2). Normalcy 
rate is an estimation ofspecificity in patients with a low pretest 
likelihood of coronary artery disease and in whom the absence 
of disease has not been confirmed by angiography. 
Inclusion criteria for group 1 (n = 143) were signs and 
symptoms of coronary artery disease and angiographic evi- 
dence (->50% stenosis) of coronary artery disease within 14 
weeks of the study. A subset of group l (n = 114) also 
Table 1. Patient Characteristics 
Group 2 
Group 1 (low likelihood 
(CAD, n = 143) of CAD, n = 54) 
Age (yr) 
Mean _+ SD 59 + 1() 43 _+ 13 
Range 37 79 20-70 
Men 121 (85) 52 (96) 
Women 22 ( 15 ) 2 (4) 
Prior MI 67 (47) [) 
Angina 130 (91) f) 
CAD 
One vessel 45 (31) NA 
Multivessel 98 (69) NA 
Risk Factors 
Hyperlipidemia 79 (55) 33 (61) 
Nonanginal chest pain UA 25 (46) 
Smoking 62 (43) 23 (43) 
Hypertension 7(1 (49) 12 (22) 
Diabetes mellitus 25 (17) 1 (2) 
Data presented are number (%) of patients, unless otherwise indicated. 
CAD = coronary artery disease: MI = myocardial infarction; NA = not 
applicable (coronary angiography not required): UA = unavailable. 
performed exercise chocardiography within 2 weeks of the 
arbutamine stress test. In these patients, the order of testing 
was randomly assigned. An additional 16 patients who had 
negative (<50% stenosis) angiographic results were excluded 
by study design from group 1. Eleven of these patients had 
echocardiographic signs of ischemia during arbutamine t st- 
ing; however, 7of 11 had at least one major artery with ->40% 
stenosis, and 10 of 11 had a history of angina or prior 
myocardial infarction, or both. The small number of patients 
and the bias toward patients with functionally significant 
disease, despite negative angiography, made this estimate of 
specificity unreliable. Specificity, by study design, was deter- 
mined in group 2 (n = 54), the low likelihood group of patients 
who were referred for evaluation of coronary artery disease 
and had nonspecific hest pain or cardiac risk factors, or both. 
In addition, these patients had negative maximal exercise 
treadmill test results within 12 weeks of the study and an 
exercise treadmill nomogram score indicating ->98% probabil- 
ity of 5-year survival (9). Patients with unstable angina or 
myocardial infarction within 30 days, coronary artery bypass 
graft surgery, percutaneous transluminal coronary angioplasty 
within 3 months, significant arrhythmias, congestive heart 
failure (New York Heart Association functional class III or 
IV), cardiomyopathy, significant valvular heart disease or 
uncontrolled systemic hypertension (systolic blood pressure 
> 180 mm Hg) were excluded from study. The protocols used 
in this study were approved by the Institutional Review Board 
or Ethics Review Committee of each participating site, and all 
patients gave written informed consent. 
Stress protocols. Beta-adrenergic blocking medications 
were withheld at least 48 h before the stress tests. Atropine was 
excluded 24 h before the stress tests and was not administered 
during or immediately after stress. Symptom-limited arbu- 
tamine and exercise tests were performed. End points for 
stopping either stress test were electrocardiographic (ECG) 
ischemia (ST segment deviation ->2.0 mm), intolerable symp- 
toms, significant arrhythmias or achievement of target heart 
rate. The maximal heart rate was 85% of age-predicted 
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maximal heart rate for arbutamine, but exercise could exceed 
this limit. Other end points for arbutamine stress testing 
included heart rate saturation (maximal heart rate response 
without achieving target), ischemia ssessed by echocardiogra- 
phy (new or worsening wall motion abnormalities in three or 
more segments) or maximal total dose. All expected and 
unexpected side effects for both types of stress were recorded, 
and information on all arrhythmias was collected, regardless of 
clinical significance. 
Arbutamine protocol. Arbutamine was infused intrave- 
nously by a computerized, heart rate feedback (closed-loop) 
delivery device that monitored heart rate at 5-s intervals and 
blood pressure at 2-rain intervals. The device infuses arbu- 
tamine according to a predetermined rate of heart rate in- 
crease (heart rate slope) and maximal heart rate (heart rate 
target). For this study, the selected heart rate slope was 8 
beats/rain per min, and the selected heart rate target was 85% 
of age-predicted maximal heart rate. The predefined maximal 
infusion rate and total dose of arbutamine were 0.8/zg/kg body 
weight per min and 10 tLg/kg, respectively. The device issued 
audible and visual alerts and alarms and automatically inter- 
rupted the infusion if heart rate or blood pressure changes 
exceeded preprogrammed limits. 
Echocardiograms were recorded at baseline, at 20 beats/' 
rain above baseline heart rate, at end of infusion and at 10 min 
into recovery. Twelve-lead ECGs were recorded at 2-min 
intervals. 
Exercise protocol. Exercise echocardiography was per- 
formed in a subset of group 1 patients using either treadmill 
(Bruce or Naughton protocols) or upright bicycle exercise. 
Echocardiograms were obtained at rest, immediately after 
exercise and 10 rain into recovery. Heart rate, blood pressure 
and 12-lead ECGs were recorded at each stage of exercise. 
Echocardiographic analysis. Echocardiographic images 
(parasternal long- and short-axis, apical four- and two- 
chamber views) were obtained at each stage during the stress 
tests and, in the majority of cases (84%), digitized on-line. The 
left ventricle was divided into a standard 16-segment model, 
and wall motion was scored as 1 = normal; 2 = hypokinetic; 
3 = akinetic; or 4 = dyskinetic. In addition, left ventricular 
ejection fraction (single-plane Simpson's rule) was calculated 
at each stage. Echocardiograms were reviewed at a central core 
facility by experienced observers in blinded manner. The 
diagnosis of ischemia was made if a new or worsening stress- 
induced wall motion abnormality occurred in one anterior 
segment or two adjacent posterior segments, or both. The 
diagnosis of coronary artery disease was made if either a rest or 
induced wall motion abnormality was present. 
Electrocardiographic analysis. Twelve-lead ECGs were 
analyzed at a central core facility by experienced observers in 
a blinded manner. Ischemia was diagnosed if > 1.0-ram hori- 
zontal or downsloping ST depression or > 1.0-mm ST segment 
elevation in leads without Q waves occurred 60 ms after the J 
point. 
Coronary angiography. Coronary angiography in group l 
was performed according to standard clinical practice at each 
investigational site. Coronary angiograms were analyzed at a 
central core facility by experienced observers in a blinded 
manner. The boundaries of a selected coronary arterial seg- 
ment were digitized and magnified by the Image Comm System 
(Image Comm, Inc.) (10). The diameter of the coronary 
catheter was used for size calibration: the mean diameter in 
pixels was compared with the known size in millimeters. The 
analysis oftware identified the coronary artery borders in the 
optimal cineangiographic view using a double-differentiated 
approximation and interactive operator interpolation. The 
proximal and distal ends, point of maximal stenosis and normal 
segment as the reference region were identified, and the 
maximal percent diameter stenosis was calculated. A signifi- 
cant coronary lesion was defined as ->50% diameter stenosis. 
Statistical analysis. Data are summarized asmean value _+ 
SD or number (percent) of patients. All statistical tests were 
performed at the 0.05 significance level except for tests for 
unequal carryover effects performed at the 0.10 level. Effect on 
changes in hemodynamic variables from baseline was assessed 
at the end of arbutamine infusion or exercise using a one- 
sample t test or a signed-rank test. Maximal hemodynamic 
changes were compared between the two stress tests using a 
repeated-measures analysis of variance (ANOVA) or a rank- 
transformed ANOVA for two-period crossover data. Point and 
95% confidence binomial interval estimates for sensitivity in 
the diagnosis of ischemia (from echocardiography or electro- 
cardiography) and coronary artery disease (from echocardiog- 
raphy) were provided for each stress test. Sensitivities were 
compared using the Fisher exact est or a continuity-corrected 
chi-square test for crossover data. Similar point and interval 
estimates of specificity (normalcy) were provided. Correlates 
of negative ischemia results in patients with coronary artery 
disease were examined by comparing patients with and without 
ischemia using the Wilcoxon rank-sum test or the Fisher exact 
test. Differences or trends among subgroups (number of 
diseased vessels, maximal percent stenosis) were examined 
using the Cochran-Mantel-Haenszel test. 
Resu l ts  
Arbutamine dose and stress duration. The total dose of 
arbutamine administered in group 2 (low likelihood) patients 
(4.62 _+ 1.78 txg/kg, n = 53) was greater than in group 1 
(coronary artery disease) patients (3.58 - 2.54/zg/kg, n = 134). 
The overall arbutamine t st duration was longer in group 2 
(18.1 _+ 5.6 min) than in group 1 (16.4 _+ 8.4 rain). The overall 
exercise duration in group 1 (7.5 _+ 3.0 minutes, n = 114) was 
shorter than the infusion time for either arbutamine group. 
Hemodynamic response to arbutamine and exercise. Com- 
parison of the hemodynamic response in group 1 patients who 
had both stress test data is shown in Figure 2. Heart rate, 
systolic blood pressure, rate-pressure product and ejection 
fraction increased significantly in response to both forms of 
stress (p -< 0.001). The peak increases in heart rate, systolic 
blood pressure and rate-pressure product were significantly 
greater with exercise than with arbutamine (Table 2). In 
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Figure 2. Hemodynamic response toarbutamine (squares) 
and exercise (circles) in patients with coronary artery dis- 
ease (group 1). Numbers epresent mean values. Error bars 
represent SD. Basal versus peak comparisons for all vari- 
ables for both arbutamine and exercise were statistically 
significant (p -< 0.001). bpm = beats per minute. 
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contrast, ejection fraction increased significantly more with 
arbutamine (p = 0.025). Additionally, the peak percent age- 
predicted maximal heart rate was higher with exercise than 
with arbutamine (86 _ 12% vs. 77 _+ 9%, respectively, p < 
0.001). In patients with a low likelihood of coronary artery 
disease (group 2), heart rate, systolic blood pressure, rate- 
pressure product and ejection fraction also increased signifi- 
cantly with arbutamine stress, and to a greater extent han in 
group 1. 
Diagnostic e~cacy of arbutamine and exercise eehocardi- 
ography. The overall incidence of arbutamine provoking myo- 
cardial ischemia (new or worsening wall motion abnormalities) 
was 76% (95% confidence interval [CI] 67% to 83%, 96 of 127 
patients). Ischemia results in the subset of group 1 patients 
with both arbutamine and exercise results (n = 98) were 
Table 2. Peak Increases inHemodynamic Variables in 107 Patients 
(group 1) With Both Arbutamine and Exercise Test Results 
Arbutamine Exercise p 
(mean + SD) (mean +_ SD) Value 
HR increase (beats/rain) 54 _+ 13 58 + 20 0.033 
Systolic BP increase (ram Hg) 37 _+ 16 47 _+ 24 < 0.001 
Rate-pressure product increase 9545 _+ 3,356 14,123 =5,196 < 0.001 
(ram Hg x beats/rain) 
LVEF increase (%)* 13 _+ 1 ] 9 + 10 0,025 
*n = 104. BP = blood pressure; HR = heart rate; LVEF = left ventricular 
ejection fraction. 
similar (79% [95% CI 69% to 86%] and 77% [95% CI 67% to 
85%], respectively). The overall sensitivity for diagnosing 
coronary artery disease (rest or new or worsening wall motion 
abnormalities) using arbutamine chocardiography was 84% 
(95% CI 77% to 90%, 110 of 131 patients). Sensitivity results 
Table 3. Subgroup Analyses of Patients With Coronary Artery 
Disease (group 1) Who Performed Arbutamine and 
Exercise Echocardiography* 
Arbutamine Exercise 
Incidence of Incidence of 
No. of Ischemia 95% C1 Ischemia 95% CI 
Pts. (%) (%) (%) (%) 
Prior MI 
No 49 73 59-85 69 55-82 
Yes 49 84 70-93 84 70-93 
CAD 
1-vessel 31 71 52-86 77 59-90 
2-vessel 39 85 70 -94 74 58 - 87 
3-vessel 28 79 59 -92 79 59 -92 
8tenosis 
50-74.9% 31 74 55-88 68 49-83 
75-8%9% 16 81 54-96 75 48-93 
->90% 51 80 67-90 82 69-92 
*Group 1 had ->50% stenosis by coronary angiography. None of the 
comparisons for incidence of ischemia between arbutamine and exercise cho- 
cardiography were statistically significant (p > 0.05). CI = confidence interval; 
Pts = patients: other abbreviations a in Table 1. 
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Table 4. Reasons for Terminating Stress Testing* 
Group 2 
flow likelihood 
Group 1 (CAD) of CAD): 
Exercise Arbutamine Arbutamine 
(n - 114) (n - 143) (n - 54) 
Target HR attained 57 (50) 54 (38) 7 (13) 
Angina 23 (20) 30 (21) 0 (0) 
HR saturation NA 22 (15) 40 (74) 
->2 mm ST segment 23 (20) 21 (15) 0 (0) 
deviation 
->3 WMA NA 9 (~) 0 (0) 
Arrhythmia 1(1) a (4) 1(2) 
Hypotension 1 ( 1 ) 6 (4) 5 (9) 
Dyspnea 12 (11) 6 (4) 0 (0) 
Fatigue 24 (21) 0 (0) 0 (0) 
*Patients could have more than one reason to stop stress testing. Data 
presented are number (%) of patients. WMA - wall motion abnormalities; other 
abbreviations as in Tables 1 and 2. 
in the subset of group 1 patients with both arbutamine and 
exercise data (n = 101) were similar (87% [95% CI 79% to 
93%] and 83% [95% CI 74% to 90%], respectively). The 
specificity or normalcy rate of arbutamine echocardiography in 
group 2 was 96% (95% CI 87% to 100%, 50 of 52 patients). 
Sensitivity analyses of patient subgroups. Subgroup analyses 
(Table 3) were performed in patients with coronary artery 
disease (group 1) who underwent both arbutamine and exer- 
cise echocardiography. In patients with prior myocardial in- 
farction, the incidence of ischemia detected by echocardiogra- 
phy was higher with either arbutamine or exercise stress than 
in patients without prior infarction. The incidence of ischemia 
was not significantly different among patients with single-, 
double- and triple-vessel coronary artery disease or with 
increasing stenosis everity for arbutamine or exercise stress. 
Concordance of arbutamine and exercise results. The results 
for different patient groups howed arbutamine to be similar to 
exercise. The percent of agreement between the two stress 
tests for the incidence of ischemia by echocardiography was 
80% (66 arbutamine/exercise +/+ and 12 arbutamine/exercisc 
- / -  of 98 group 1 patients). Discordant results were equally 
distributed for the two stress tests (11 arbutamine +/exercise - 
and 9 exercise +/arbutamine -). 
Negative arbutamine ischemia in patients" with corona~ artery 
disease. To determine their possible association with the fail- 
ure to induce ischemia with arbutamine, various factors were 
compared in coronary artery disease (group 1) patients without 
ischemic responses (n = 31) with those with positive results 
(n = 96). The correlates evaluated were maximal heart rate, 
maximal systolic blood pressure, percent age-predicted maxi- 
mal heart rate, angiographic variables (single-vessel, maximal 
percent stenosis), test outcomes (reasons to stop stress) (Table 
4) and concordance with exercise echocardiographic results. 
Of these, a significant difference between patients with nega- 
tive and positive arbutamine t st results was observed only with 
the concomitant inability to provoke ischemia with exercise 
(negative 39% vs. positive 11%. p = 0.002). 
Positive arbutamine ischemia in patients with low likelihood 
of disease. Two patients with a low likelihood of disease 
(group 2) had arbutamine stress echocardiographic results 
indicating myocardial ischemia. Both patients had baseline 
evidence of coronary artery disease as determined by the 
central aboratories; one patient had diagnostic ECG Q waves, 
and the other had rest echocardiographic wall motion abnor- 
malities. 
Diagnostic efficacy of arbutamine and exercise lectrocar. 
diography. The sensitivity of detecting coronary artery disease 
by electrocardiography in group 1 patients with both stress test 
results (n = 111) was 49% (95% confidence interval [CI] 39% 
to 58%) with arbutamine and 47% (95% CI 37% to 57%) with 
exercise. The specificity (normalcy) of arbutamine lectrocar- 
diography (group 2) for excluding ischemia was 80% (95% CI 
67% to 89%, n = 54). 
Side effects. There were no deaths or serious side effects 
during the study. The majority of side effects were mild and 
resolved spontaneously at the end of infusion or exercise. 
Noncardiac events. Arbutamine noncardiac side effects, 
commonly associated with catecholamines, were found more 
frequently in patients with low likelihood of disease (group 2) 
than in those with coronary artery disease (group 1): tremor 
(22% and 8%, respectively), headache (11% and 8%, respec- 
tively), dizziness (11% and 1%, respectively) and burning or 
tingling (7% and 1%, respectively). 
Hypotension. Hypotension was observed twice as often in 
patients with a low likelihood of disease (group 2) (9%) as in 
those with coronary artery disease (group 1) (4%) and was not 
found to correlate with extent of coronary artery disease (in 
group 1, three patients had one-vessel, two had two-vessel, and 
one had three-vessel disease). All episodes of hypotension 
resolved spontaneously with the end of infusion. 
Angina. Angina occurred with similar frequency during 
arbutamine (45%) and exercise (40%) testing in patients with 
coronary artery disease (group 1). Sublingual nitrates or 
intravenous beta-blockers, orboth, were given for angina in 14 
patients after arbutamine and 5 patients after exercise. Angina 
did not occur in patients with a low likelihood of disease 
(group 2); nonspecific chest pain was reported in three group 
2 patients (6%). 
Arrhythmias. Arrhythmias were observed in the majority of 
patients during exercise testing (52% in group 1 with coronary 
artery disease) as well as during arbutamine testing (72% in 
group 1 and 54% in group 2 with a low likelihood of disease). 
The most common arrhythmias were isolated premature atrial 
and ventricular beats of no clinical significance (Table 5). Of 
all observed arrhythmias, only a small proportion were consid- 
ered clinically significant (reported by the investigator as 
adverse vents). These arrhythmias occurred uring exercise in 
four group 1 patients (4%) (one with nonsustained [<30 beats] 
ventricular tachycardia, one with premature atrial and ventric- 
ular contractions, one each with ventricular bigeminy and sinus 
bradycardia) nd during arbutamine infusion in eight group 1 
patients (6%) (one with nonsustained ventricular tachycardia, 
three with supraventricular t chycardia, one each with prema- 
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Table 5. All Arrhythmias Observed During Arbutamine and Exercise Stress 
Group 1 (CAD) 
Exercise Arbutamine 
(n 114) (n - 143) 
Group 2 
(low likelihood of CAD): 
Arbutamine (n - 54) 
Arrhythmias 59 (52) 103 (72) 29 (54) 
Premature atrial contraction 17 (15) 36 (25) 15 (28) 
Supraventricular t chycardia 1 (1) 8 (6) 4 (7) 
Junctional rhythm 0 (0) 7 (5) 4 (7) 
Junctional tachycardia 0 (0) 2 (1) 1 (2) 
Premature ventricular contraction 50 (44) 92 (64) 22 (41) 
Idioventricular rhythm 0 (0) 3 (2) 1 (2) 
Nonsustained ventricular tachycardia 1 (1) 6 (4) 0 (0) 
Sinus bradycardia 1 (1) 0 (0) 0 (0) 
Data presented are number (%) of patients. CAD = coronaD' artery disease. 
ture ventricular contractions, ventricular bigeminy, junctional 
rhythm and idioventricular rhythm) and two group 2 patients 
(4%) (both with junctional rhythm). In group 1 patients with 
clinically significant arrhythmias, seven of eight arbutamine 
tests and three of four exercise tests were associated with 
concomitant ischemia by echocardiographic or ECG criteria, 
or both. Only two patients received treatment for arrhythmias: 
One group 1 patient with persistent ST segment depression 
and ventricular bigeminy was treated with intravenous pro- 
pranolol, and one group 2 patient with junctional rhythm was 
treated with intravenous atropine. All arrhythmias resolved 
without sequelae. 
Discuss ion  
The major findings of this study were 1) arbutamine ffec- 
tively provoked myocardial ischemia (76%) and identified 
coronary artery disease (84%) by echocardiography in patients 
with coronary angiographic evidence of disease (group 1); 2) 
the efficacy of arbutamine chocardiography was almost iden- 
tical to the more established technique of exercise chocardi- 
ography; 3) the specificity or normalcy rate of 96% (in group 2 
patients) indicated that arbutamine stress echocardiography is 
an effective means of excluding coronary artery disease; and 4) 
the arbutamine system was well tolerated and had an accept- 
able safety profile. 
E~eaey of arbutamine ehocardiography. The sensitivity 
of detecting coronary artery disease by exercise and arbu- 
tamine echocardiography in the present study compares favor- 
ably with previous reports of exercise and dobutamine cho- 
cardiography (11-20). In the present study, the sensitivity of 
arbutamine was compared with the more established tech- 
niques of exercise chocardiography and electrocardiography. 
The results were almost identical, not only in the overall cohort 
with coronary artery disease, but also in the subgroups that 
were examined. Other studies (13,18) have also shown similar 
comparisons of sensitivity between dobutamine and exercise 
echocardiography. The sensitivity results for exercise chocar- 
diography in the present study were similar to those of 
previous reports (15,16), validating results in comparing arbu- 
tamine with exercise echocardiography. In addition, the con- 
cordance between arbutamine and exercise in provoking isch- 
emia (80%) was similar to that of a previous comparison study 
(13). Finally, the efficacy of the stress ECG data was compa- 
rable to that noted by other investigators (11,19,20). 
Determination of specific causes for negative ischemia 
results in patients with coronary artery disease (group 1) was 
inconclusive. The failure to induce ischemia probably reflects a
variety of mechanisms and individual response patterns to the 
drug and the delivery system. The only significant correlate of 
negative ischemic results with arbutamine was the concordant 
inability to provoke ischemia with exercise stress. This inability 
suggests that these patients may have had less functionally 
significant coronary artery disease. Previous reports (1-3,5,13- 
15,17,20) of exercise and dobutamine chocardiography ave 
also shown milder degrees of coronary artery disease to be 
associated with negative ischemia results. 
The normalcy rate of arbutamine chocardiography to 
exclude coronary artery disease was similar to specificity rates 
(3,14,19) and to normalcy rates (21,22) reported with dobut- 
amine echocardiography. Because the prevalence of disease is 
5% in the asymptomatic population (23) and 10% in patients 
with nonanginal chest pain (24), 3 to 5 patients with coronary 
artery disease could have been expected in the 54 patients 
comprising the normalcy group. In the present study, both 
patients with positive results were older (>60 years old) and 
had baseline ECG or echocardiographic evidence of coronary 
artery disease. The diagnoses were not confirmed with angiog- 
raphy; however, one patient with baseline Q waves also had 
nonreversible perfusion defects on thallium-201 SPECT per- 
fusion imaging. 
Hemodynamic response to arbutamine and exercise. Heart 
rate, systolic blood pressure, rate-pressure product and ejec- 
tion fraction increased, as expected, in response to both 
arbutamine and exercise stress. With the exception of ejection 
fraction, the peak physiologic values were higher with exercise 
than with arbutamine, which may be partially explained by 
differences in patient positioning, heart rate saturation and 
differences in maximal heart rate targets. The supine position 
of the patient during arbutamine infusion caused lower base- 
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line heart rates and blood pressures than during exercise. The 
heart rate saturation phenomenon, whereby further increases 
in heart rate are not observed with increasing doses of 
arbutamine, has also been described uring dobutamine stress 
testing (11) and probably represents a limitation of beta- 
adrenoceptor stimulation or a reflex increase in parasympa- 
thetic tone (11,12). Importantly, the protocol allowed exercise 
to continue beyond 85% of the age-predicted maximal heart 
rate, and, in fact, -50% of the patients performing exercise 
exceeded the 85% target. The observation that diagnostic 
sensitivity can be obtained with pharmacologic stress testing at 
heart rates lower than exercise has been reported with dobut- 
amine stress echocardiography (13,14,25) and may apply to 
arbutamine stress echocardiography as well. In addition, the 
higher peak ejection fraction seen with arbutamine may reflect 
a greater inotropic effect of arbutamine than exercise, which 
may have contributed to the induction of ischemia. A similar 
possibility was noted when dobutamine was compared to 
exercise chocardiography (13). 
Side effects. There were no deaths or serious adverse 
events during the study, and the drug was well tolerated. The 
side effects observed in this study were similar to those 
reported previously with dobutamine echocardiography 
(3,5,11,13,19,20,26,27). The increased occurrence of certain 
side effects (e.g., tremor and headache) in patients with a low 
likelihood of disease (group 2) may result from the observation 
that they did not have intervening ischemic symptoms or events 
that would prematurely terminate the arbutamine infusion. 
Therefore, patients received higher doses of drug and may also 
have had a heightened awareness of minor symptoms. Hypo- 
tension isprobably caused by the peripheral vasodilatory effects 
or the vasodepressor reflex response seen with beta-agonists 
(28,29). As previously described with dobutamine chocardi- 
ography (28), hypotension during arbutamine stress was not 
associated with presence or severity of coronary artery disease. 
Arrhythmias were more common with arbutamine than with 
exercise, reflecting the effects of catecholamine stimulation. 
However, concomitant ischemia could have been a contribut- 
ing factor because all but two tests in patients with coronary 
artery disease (group 1) with clinically significant arrhythmias 
were associated with echocardiographic or ECG ischemia, or 
both. 
Advantages of arbutamine echocardiography. Arbu- 
tamine, with its unique chronotropic and inotropic properties, 
effectively increases cardiac work and may decrease coronary 
perfusion, thereby provoking myocardial ischemia (6). As with 
other pharmacologic stress agents uch as dobutamine, arbu- 
tamine's ability to induce ischemia while the patient remains 
stationary facilitates the acquisition of high quality echocardio- 
graphic images. Arbutamine was specifically developed as a 
stress agent o have a more pronounced chronotropic response 
than dobutamine, mphasizing the contribution of heart rate 
to the development of myocardial ischemia (8). Arbutamine 
and the closed-loop delivery system have effectively induced 
ischemia without the addition of atropine, which is used in 
some clinical sites in 30% to 40~ of patients to augment the 
chronotropic response of dobutarnine (26,27). The chrono- 
tropic properties of arbutamine also enabled the development 
of a closed-loop (feedback) algorithm to automatically adjust 
the rate of infusion on the basis of the patient's heart rate 
response. The individual dose titration allows precise control 
of the rate of increase up to the selected maximal heart rate 
and minimizes the total dose of drug given. In addition, the 
delivery device provides frequent heart rate and blood pres- 
sure monitoring and an alert/alarm system to warn the physi- 
cian of unexpected changes in hemodynamic variables or to 
stop the infusion, if appropriate. The combination of arbu- 
tamine and its delivery system allows the physician to focus on 
the patient's condition and the acquisition of echocardio- 
graphic images. 
Study limitations. Patients in the present study were se- 
lected from two distinct patient groups and therefore did not 
fully represent the clinical population in which stress testing is 
routinely performed. The decision to evaluate normalcy rather 
than specificity in patients with negative angiographic results 
(<50% stenosis) was based on the known limitations of 
coronary angiography and is consistent with recent clinical 
practice (21,22,30,31). Although coronary angiography is a 
good anatomic indicator of coronary artery disease, it is not the 
definitive standard for evaluating function or prognosis. In 
addition, because of the attendant risks and cost associated 
with angiography, requiring an invasive procedure in patients 
with a low risk of disease may not be ethically appropriate. 
Furthermore, pretest and posttest selection biases may result 
in lower apparent specificity (21), as was seen in the few 
patients with negative angiographic results. It should also be 
noted that the normalcy group did not consist of normal 
volunteers, as evidenced by a relatively high incidence of 
cardiac risk factors, and represented a significant portion of the 
clinical population who would be referred for stress echocar- 
diography. In patients with angiographic evidence of coronary 
disease, the detection of myocardial ischemia may have been 
favored by including patients with prior myocardial infarc- 
tion because these patients are more likely to have left 
ventricular dysfunction and more severe coronary artery 
disease. 
Although the efficacy results did not appear to be compro- 
mised, the use of different heart rate end points for arbutamine 
and exercise may have affected comparisons of the two forms 
of stress. As noted earlier, the exercise test often went beyond 
85% of the age-predicted maximal heart rate, whereas the 
arbutamine test was limited to 85% of age-predicted maximal 
heart rate. Further study to evaluate the optimal heart rate 
target for arbutamine stress may be appropriate. Finally, the 
effect of concomitant beta-blocker therapy on the sensitivity of 
the arbutamine stress test was not tested. 
Conclusions. The present study demonstrates that arbu- 
tamine echocardiography is an effective technique for provok- 
ing myocardial ischemia and diagnosing or excluding coronary 
artery disease and is comparable to exercise ehocardiography. 
The drug is well tolerated and has an acceptable safety profile. 
The closed-loop drug delivery device provides individualized 
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dosing and a system to monitor the patient's hemodynamic 
status and warn of potentially significant clinical conditions. 
Arbutamine echocardiography represents an important new 
method for detecting coronary artery disease. 
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